Promising ROSELLA Study Boosts Buy Rating for Corcept Therapeutics with Relacorilant’s Potential in Ovarian Cancer Treatment

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Corcept Therapeutics (CORT – Research Report), with a price target of $145.00.

Swayampakula Ramakanth’s rating is based on the promising data from the ROSELLA study, which highlights relacorilant’s potential in treating ovarian cancer. The study demonstrated that relacorilant, when combined with nab-paclitaxel, significantly improved progression-free survival and overall survival rates compared to nab-paclitaxel alone. This suggests that relacorilant could become a preferred treatment option for patients with platinum-resistant ovarian cancer, potentially leading to substantial sales growth in the coming years.
Additionally, the safety profile of relacorilant was favorable, with no added toxicity compared to the standard treatment. The manageable side effects and the potential to reduce the incidence of ascites further support its clinical value. These factors, combined with a robust valuation analysis, underpin the Buy rating and the price target of $145 per share, reflecting confidence in Corcept Therapeutics’ future growth prospects.

Based on the recent corporate insider activity of 130 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CORT in relation to earlier this year.